Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CFO David Jin purchased 7,605 shares of the business’s stock in a transaction that occurred on Thursday, November 19th. The stock was acquired at an average price of $1.87 per share, for a total transaction of $14,221.35. Following the acquisition, the chief financial officer directly owned 1,700,366 shares of the company’s stock, valued at $3,179,684.42. This trade represents a 0.45% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.
David Jin also recently made the following trade(s):
- On Wednesday, November 18th, David Jin bought 25,000 shares of Fortress Biotech stock. The stock was acquired at an average cost of $1.91 per share, for a total transaction of $47,750.00.
- On Tuesday, November 17th, David Jin purchased 15,000 shares of Fortress Biotech stock. The stock was bought at an average price of $1.72 per share, with a total value of $25,800.00.
Fortress Biotech Stock Down 5.7%
NASDAQ:FBIO traded down $0.11 during mid-day trading on Thursday, hitting $1.78. The company had a trading volume of 194,841 shares, compared to its average volume of 586,980. The business has a fifty day simple moving average of $2.08 and a 200-day simple moving average of $2.70. The company has a current ratio of 2.93, a quick ratio of 3.83 and a debt-to-equity ratio of 0.10. Fortress Biotech, Inc. has a 1 year low of $1.64 and a 1 year high of $4.53. The firm has a market capitalization of $60.16 million, a price-to-earnings ratio of 0.78 and a beta of 1.27.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last issued its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%. The company had revenue of $19.16 million during the quarter, compared to the consensus estimate of $21.57 million.
Wall Street Analysts Forecast Growth
FBIO has been the subject of a number of analyst reports. Weiss Ratings cut Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Wall Street Zen lowered shares of Fortress Biotech from a “strong-buy” rating to a “hold” rating in a report on Saturday, August 15th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.00.
Get Our Latest Analysis on Fortress Biotech
Key Fortress Biotech News
Here’s some of the latest news about FBIO:
- Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
- Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of FBIO. Marshall Wace LLP bought a new stake in shares of Fortress Biotech in the 3rd quarter valued at approximately $462,000. Squarepoint Ops LLC bought a new position in Fortress Biotech during the second quarter worth $47,000. Finally, Renaissance Technologies LLC lifted its stake in Fortress Biotech by 22.8% during the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 18,490 shares during the last quarter. Institutional investors own 96.51% of the company’s stock.
Fortress Biotech Company Profile
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Read More
- Five stocks we like better than Fortress Biotech
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
